Erika Hamilton: Excited to see further updates from monarchE at ESMO23.

Erika Hamilton, made the following post on LinkedIn:

“Excited to see further updates from monarchE at ESMO23. This study cemented adjuvant abemaciclib as a treatment for high risk patients with ER+ early breast cancer defined by nodal status, and tumor size and grade.

The below interview was updated findings by age presented at this past ASCO23.”

For details click here.
Source: Erika Hamilton/LinkedIn

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective. Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.